Ubs Asset Management Americas Inc Neurocrine Biosciences Inc Transaction History
Ubs Asset Management Americas Inc
- $417 Billion
- Q4 2024
A detailed history of Ubs Asset Management Americas Inc transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 1,070,096 shares of NBIX stock, worth $121 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
1,070,096
Previous 894,217
19.67%
Holding current value
$121 Million
Previous $103 Million
41.88%
% of portfolio
0.03%
Previous 0.03%
Shares
29 transactions
Others Institutions Holding NBIX
# of Institutions
655Shares Held
96.6MCall Options Held
282KPut Options Held
281K-
Black Rock Inc. New York, NY14.2MShares$1.6 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$1.14 Billion0.02% of portfolio
-
State Street Corp Boston, MA4.89MShares$553 Million0.03% of portfolio
-
Dodge & Cox San Francisco, CA3.02MShares$341 Million0.26% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.54MShares$287 Million0.06% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $10.8B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...